cancer

Novartis, Broad researchers find hope in potential gene target for intractable cancers
Novartis, Broad researchers find hope in potential gene target for intractable cancers
BioPharma Dive
Novartis
cancer
R&D
Flag link:
He Built Google Maps. Now He'll Lead The Development Of A Blood Test For Cancer
He Built Google Maps. Now He'll Lead The Development Of A Blood Test For Cancer
Forbes
Jeff Huber
cancer
Google
Grail
diagnostics
Flag link:
Merck bets up to $515M on an epigenetic project for cancer and blood disease
Merck bets up to $515M on an epigenetic project for cancer and blood disease
Fierce Biotech
Merck
epigenetics
CRUK
blood disease
cancer
R&D
Flag link:
Illumina Starts Cancer Blood Test Firm With Bezos, Gates Backing
Illumina Starts Cancer Blood Test Firm With Bezos, Gates Backing
Bloomberg
Illumina
Jeff Bezos
Bill Gates
diagnostics
cancer
Grail
genetic sequencing
Flag link:
Eli Lilly, Pfizer, J&J, AbbVie Join $48M Bet On NYC Cancer Drug Startup
Eli Lilly, Pfizer, J&J, AbbVie Join $48M Bet On NYC Cancer Drug Startup
Forbes
Eli Lilly
Pfizer
JNJ
AbbVie
Petra Pharma
cancer
Flag link:
What Accounts For Low Enrollment In Clinical Trials For Cancer Drugs?
What Accounts For Low Enrollment In Clinical Trials For Cancer Drugs?
Forbes
clinical trials
cancer
Flag link:
Insurers Don't Want to Pay for Pricey Cancer Meds
Insurers Don't Want to Pay for Pricey Cancer Meds
Motley Fool
insurers
cancer
Flag link:
3 Cancer Companies to Watch Closely in 2016
3 Cancer Companies to Watch Closely in 2016
Motley Fool
cancer
Celldex
Medivation
Clovis Oncology
rociletinib
talazoparib
Rintega
Flag link:
Merck, Incyte eye a winning cancer combo with widened collaboration
Merck, Incyte eye a winning cancer combo with widened collaboration
Fierce Biotech
Merck
Incyte
cancer
Keytruda
epacadostat
Flag link:
Merck KGaA bets on cancer drugs to revitalize German firm
Merck KGaA bets on cancer drugs to revitalize German firm
Yahoo/Reuters
Merck KGaA
cancer
Merck Serono
Rebif
Erbitux
Flag link:
Cancer Vaccines Make a Comeback, As Third Rock Pumps $55M Into Neon Therapeutics
Cancer Vaccines Make a Comeback, As Third Rock Pumps $55M Into Neon Therapeutics
Forbes
cancer
vaccines
Third Rock
Neon Therapeutics
Flag link:
Xoma enters exclusive license agreement with Novartis
Xoma enters exclusive license agreement with Novartis
Marketwatch
Xoma
Novartis
cancer
antibodies
Flag link:
Execs behind Imbruvica raise $75M for a new cancer project
Execs behind Imbruvica raise $75M for a new cancer project
Fierce Biotech
Imbruvica
Corbus Pharmaceuticals
cancer
Flag link:
Rexahn's Human Data Confirms Anti-Cancer Advantage
Rexahn's Human Data Confirms Anti-Cancer Advantage
Yahoo
Rexahn
RX-3117
Supinoxin
cancer
Flag link:
Sorrento launches another joint venture with a $170M cancer deal
Sorrento launches another joint venture with a $170M cancer deal
Fierce Biotech
Sorrento Therapeutics
R&D
cancer
antibodies
Flag link:
Pfizer says it could be leader in cancer with many new drugs
Pfizer says it could be leader in cancer with many new drugs
Yahoo/AP
Pfizer
cancer
immuno-oncology
Flag link:
Amgen, Xencor In $1.75 Billion Cancer Drug Alliance
Amgen, Xencor In $1.75 Billion Cancer Drug Alliance
Investors.com
Amgen
Xencor
cancer
Flag link:
Roche CEO Slams `Stupid' U.K. Decision to Drop Some Cancer Drugs
Roche CEO Slams `Stupid' U.K. Decision to Drop Some Cancer Drugs
Bloomberg
Roche
Pharma CEOs
UK
cancer
Avastin
Severin Schwan
Flag link:
Not just cancer: Seattle biotechs, researchers explore immunotherapy for other diseases
Not just cancer: Seattle biotechs, researchers explore immunotherapy for other diseases
Bizjournals.com
Seattle
cancer
immunotherapy
Juno Therapeutics
Flag link:
Google Reveals Gigantic Ambitions To Fight Cancer, Diabetes, Parkinson's, Heart Problems
Google Reveals Gigantic Ambitions To Fight Cancer, Diabetes, Parkinson's, Heart Problems
Forbes
Google
Alphabet
diabetes
Parkinson's Disease
cancer
heart disease
Flag link:

Pages